Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,695.32
    -588.80 (-1.13%)
     

  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Behind the brand:

'Boutique hotel at sea': Virgin Voyages CEO hails Branson's 'biggest endeavour'

On board entrepreneur's latest venture

AstraZeneca wins U.S. approval for two-in-one diabetes pill

Reuters - UK Focus

LONDON, Oct 30 (Reuters) - A new two-in-one diabetes pill from AstraZeneca (NYSE: AZN - news) has been approved by U.S. regulators, the British drugmaker said on Thursday.

The green light from the Food and Drug Administration is for Xigduo XR, which combines the company's recently launched diabetes treatment dapagliflozin with an older kind of medicine called metformin.

Xigduo XR is the first once-daily tablet combining a so-called SGLT2 inhibitor drug and metformin to win U.S. approval.

(Reporting by Ben Hirschler; editing by Jason Neely)